NVST
HealthcareEnvista Holdings Corp · Medical - Equipment & Services · $4B
What is Envista Holdings Corp?
Envista Holdings Corp. is a mid-cap dental products company headquartered in Brea, California. Spun off as an independent public company in 2019, it serves dental professionals across the globe with a broad portfolio of diagnostic, treatment, and preventive solutions.
Envista operates through two segments. Its Specialty Products & Technologies segment covers dental implant systems, prosthetics, orthodontic brackets, aligners, and related software. Its Equipment & Consumables segment supplies dental offices with digital imaging systems, treatment units, endodontic tools, restorative materials, bonding agents, and infection prevention products. Revenue flows from both recurring consumable purchases and larger capital equipment sales, giving the business a mixed but somewhat predictable demand profile.
Envista became an independent publicly traded company in 2019 and is headquartered in Brea, California.
- Dental implant systems and prosthetics
- Orthodontic brackets, aligners, and lab products
- Digital imaging and visualization systems
- Endodontic systems and restorative consumables
- Infection prevention and dental office supplies
Is NVST a Good Stock to Buy?
UQS Score rates NVST as Below Average overall, reflecting meaningful challenges across several key dimensions of business quality.
Among the five pillars, Valuation stands out as the relative bright spot — NVST's current pricing appears more attractive compared to sector peers, which may interest value-oriented investors. The Growth and Risk pillars both register as Neutral, suggesting neither a compelling expansion story nor an immediate crisis, but a company navigating a transitional period.
The Quality and Moat pillars both score as Weak, indicating that profitability metrics and competitive durability lag behind stronger players in the healthcare and dental sector.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does NVST pay dividends?
No — Envista Holdings Corp does not currently pay a dividend.
Envista does not currently pay a dividend. For a company working through a period of operational repositioning, retaining capital rather than distributing it can support balance sheet flexibility and reinvestment into product development or debt reduction. Income-focused investors should note that NVST is not structured as a yield vehicle at this time.
When does NVST report earnings?
Envista Holdings reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Envista has faced revenue headwinds in recent periods, particularly in its Equipment & Consumables segment, as dental office spending has been uneven. Management has focused on cost discipline and portfolio optimization, though the path to sustained margin recovery remains a key area for investors to monitor.
For the most recent quarter's results and guidance, visit Envista Holdings' investor relations page directly.
NVST Price History
-37.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Envista Holdings Corp?
Based on Envista Holdings Corp's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
NVST Long-term Outlook
With Growth and Risk both rated Neutral, Envista's near-term trajectory appears stable but uninspiring. The company is not positioned as a high-growth compounder, and the Weak Quality and Moat ratings suggest structural headwinds that could limit upside even if macro dental demand improves. The relatively attractive Valuation pillar indicates the market has already priced in considerable uncertainty, which could limit downside — but a meaningful re-rating would likely require demonstrated improvement in profitability and competitive positioning.
Growth drivers
- Recovery in global dental procedure volumes post-disruption
- Adoption of digital imaging and workflow software in dental practices
- Expansion of implant and orthodontic product lines in emerging markets
Key risks
- Weak competitive moat leaves NVST exposed to pricing pressure from larger rivals
- Sustained weakness in Quality metrics could limit free cash flow generation
- Elevated sensitivity to dental capital spending cycles and practice consolidation trends
NVST vs Peers
Envista operates in a competitive healthcare landscape alongside companies that serve adjacent patient and provider markets.
Hims & Hers focuses on direct-to-consumer telehealth and wellness products, contrasting with Envista's professional dental channel strategy.
Concentra operates occupational health clinics, representing a services-based healthcare model rather than Envista's product manufacturing approach.
Beta Bionics develops insulin delivery technology, competing in a distinct medical device niche compared to Envista's dental focus.
Frequently Asked Questions
What does Envista Holdings do?
Envista Holdings manufactures and markets dental products used to diagnose, treat, and prevent conditions affecting teeth, gums, and supporting bone. Its two segments cover specialty items like implants and orthodontic systems, as well as dental office equipment and everyday consumables such as restorative materials and infection prevention products.
Does NVST pay dividends?
No, Envista Holdings does not currently pay a dividend. The company is in a phase focused on operational improvement and capital allocation flexibility, making it less suitable for investors who prioritize income generation from their equity holdings.
When does NVST report earnings?
Envista reports financial results on a quarterly basis, as is standard for US-listed companies. For the exact schedule and most recent results, check the investor relations section of Envista's official website, as specific dates are subject to change.
Is NVST a good stock to buy?
The UQS Score rates NVST as Below Average, driven by Weak Quality and Moat scores. The Valuation pillar is rated Good, which may appeal to contrarian or value-oriented investors. Whether NVST fits a portfolio depends on individual risk tolerance and investment goals — the full pillar breakdown is available to Pro members.
Is NVST overvalued?
Based on the UQS Valuation pillar, NVST is currently rated Good, suggesting the stock is not considered overvalued relative to sector peers at this time. However, valuation alone does not make a complete investment case — quality and moat concerns remain relevant context.
How does NVST compare to its competitors?
Envista competes in the dental products space, while its listed peers — Hims & Hers, Concentra, and Beta Bionics — operate in adjacent but distinct healthcare niches. Direct product-level competition is limited among this peer set, though all compete for healthcare investor capital. UQS Pro shows side-by-side score comparisons.
What is NVST's market cap bracket?
Envista Holdings is classified as a mid-cap company. This places it in a segment of the market that can offer more growth potential than mega-cap peers but may carry greater volatility and less analyst coverage than the largest healthcare names.
Who founded Envista Holdings?
Envista Holdings was established as an independent public company in 2019 when it was spun off from Danaher Corporation. Its origins trace back to Danaher's dental segment, which had been built through multiple acquisitions over many years.
Is NVST a long-term quality investment?
As a long-term quality indicator, the UQS Score currently rates NVST as Below Average, with Weak scores in both Quality and Moat — the two pillars most associated with durable long-term performance. Investors focused on compounding quality over time may want to monitor whether these ratings improve before committing capital.
What is the main competitive advantage of Envista Holdings?
Envista's breadth of dental product categories — spanning implants, orthodontics, imaging, and consumables — gives it cross-selling potential within dental practices. However, the UQS Moat pillar currently rates this competitive positioning as Weak, suggesting the advantages are not yet translating into durable pricing power or returns.
What sector does NVST belong to?
Envista Holdings is classified in the Healthcare sector, specifically within the medical devices and dental products industry. Investors can explore other [healthcare sector stocks](/sector/healthcare) rated by UQS Score to compare quality profiles across the space.
Unlock Full NVST Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access full financial metrics and trend data
- ✓Compare NVST side-by-side with sector peers
- ✓See the complete Quality and Moat breakdown
- ✓Track score changes over time with alerts
- ✓Explore curated screeners for value and quality plays
Pro Analysis
NVST — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 46.9 | 32.4 | 29.0 | 49.4 | 67.9 | 76.9 | -0.2 |
| May 17, 2026 | 47.1 | 32.6 | 29.0 | 49.4 | 67.9 | 77.3 | +0.6 |
| May 9, 2026 | 46.5 | 32.1 | 29.0 | 49.3 | 67.9 | 74.4 | +2.2 |
| May 7, 2026 | 44.3 | 29.9 | 29.0 | 48.8 | 59.5 | 72.6 | -0.1 |
| May 3, 2026 | 44.4 | 29.9 | 29.0 | 48.8 | 59.5 | 73.2 | +0.1 |
| Apr 26, 2026 | 44.3 | 29.9 | 29.0 | 48.8 | 59.5 | 72.7 | +0.1 |
| Apr 22, 2026 | 44.2 | 29.9 | 29.0 | 48.8 | 59.5 | 71.6 | 0.0 |
| Apr 19, 2026 | 44.2 | 29.9 | 29.0 | 48.9 | 59.5 | 71.6 | -0.1 |
| Apr 18, 2026 | 44.3 | 29.9 | 29.0 | 48.9 | 59.5 | 72.8 | -0.9 |
| Apr 14, 2026 | 45.2 | 29.9 | 29.0 | 48.9 | 59.5 | 78.6 | -0.1 |
NVST — Pillar Breakdown
Quality
— 32.5/100 (25%)Envista Holdings Corp currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 49.4/100 (20%)Envista Holdings Corp shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 67.9/100 (15%)Envista Holdings Corp maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 76.9/100 (15%)Envista Holdings Corp appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 29/100 (25%)Envista Holdings Corp operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NVST.
Score Composition
Financial Data
More Stock Analysis
How is the NVST UQS Score Calculated?
The UQS (Unified Quality Score) for Envista Holdings Corp is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Envista Holdings Corp's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Envista Holdings Corp is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.